UK markets open in 7 hours 28 minutes
NIKKEI 225
38,202.37 -632.73 (-1.63%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
79.25 +0.26 (+0.33%) GOLD FUTURES
2,316.10 -6.20 (-0.27%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
48,726.13 -1,229.44 (-2.46%)
Valbiotis SA (ALVAL.PA)
Paris - Paris Delayed price. Currency in EUR
Add to watchlist
At close: 05:27PM CEST
| Previous close | 4.6100 |
| Open | 4.6200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 4.4400 - 4.7300 |
| 52-week range | 3.4100 - 7.5000 |
| Volume | |
| Avg. volume | 29,835 |
| Market cap | 73.6M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5900 |
| Earnings date | 29 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.90 |
Business WireValbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM•63: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes
LA ROCHELLE, France, May 22, 2023--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible) (Paris:ALVAL), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the large success of the REVERSE-IT Phase II/III clinical study on TOTUM•63. Conducted in 636 prediabetic and untreated type 2 diabetic patients (early stage), this international, multicentric, randomized and pla
© 2024 Yahoo. All rights reserved.